ClinicalTrials.gg
Active, not recruitingNCT06136819Updated Nov 2, 2026

RT-310 Dose Escalation BPH Study

A Phase 1 interventional study of RT-310 in BPH (Benign Prostatic Hyperplasia) and Lower Urinary Tract Symptoms, sponsored by Resurge Therapeutics Inc.. Active, not recruiting at 4 sites in 2 countries. Open to male participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Resurge Therapeutics Inc. · Phase 1, Interventional, and Treatment

Updated Nov 2, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
50 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Prostatic Hyperplasia with a site in Australia — none open to participants now, 4 under way, none of them phase 3. Prostatic Hyperplasia · Australia.

Planned enrollment
18th of 19
20 · median 184
Started
2024
the only one that year
Phase 1
4 of 19
none open now
Registered
18th of 19
by date

Among the 19 studies in Prostatic Hyperplasia with a site in Australia, this one is the 18th largest by planned enrollment, is the only one that started in 2024, is one of 4 in phase 1, and was the 18th registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

None of the 19 studies in Prostatic Hyperplasia with a site in Australia is open now. The open studies under Prostatic Hyperplasia, anywhere →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 50 Years to 80 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Prostatic Hyperplasia with a site in Australia as a file.
02

Study summary

RT-310, a novel implant, is intended to minimally invasive treat locally the prostate gland for the management of prostate disease, while minimizing side-effects. The objectives of the study are to assess whether RT-310 is safe and feasible for the participant population.

Read the detailed description

The RT-310 study is a first in human Phase 1 multi-center prospective, non-randomized dose escalation study to evaluate the safety and feasibility of RT-310 for treatment of Benign Prostatic Hyperplasia (BPH). Study participants will have placement of RT-310 and be followed through 180 days.

03

Conditions studied

  • BPH (Benign Prostatic Hyperplasia)
  • Lower Urinary Tract Symptoms
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male gender
  • Diagnosis of symptomatic BPH
  • Age ≥ 50 years up to 80 years
  • International Prostate Symptom Score (IPSS) ≥ 13
  • Prostate volume 30 to 80 cc per ultrasound
  • Inadequate response and/or refusal of medical therapy for LUTS

Key Exclusion Criteria:

  • Current urinary retention or at significant risk of urinary retention after drug
  • Have an obstructive or protruding median lobe of the prostate
  • Previous BPH surgical procedure or implants, urethral stricture, Any prior minimally invasive intervention (e.g. TUNA, Balloon, Microwave, Rezūm, UroLift) or surgical intervention of the prostate
  • Previous pelvic surgery or irradiation
  • History of neurogenic or atonic bladder
  • Stress urinary incontinence, mixed or urge incontinence
  • History of prostate or bladder cancer, confirmed or suspected of prostate or bladder
  • History of compromised renal function or upper urinary tract disease
  • Other co-morbidities that could impact the study results such as: severe cardiac arrhythmias uncontrolled by medications or pacemaker; congestive heart failure (NYHA) III or IV; History of uncontrolled diabetes mellitus; significant respiratory disease in which hospitalization may be required
  • Known (i.e. AIDS, post-transplant, undergoing chemotherapy)
  • No more than two documented active urinary tract infections (UTI) by culture or bacterial prostatitis within last year documented by culture (UTI is defined as >100,000 colonies per ml urine from midstream clean catch or catheterization specimen)
  • Current gross hematuria and/or visible hematuria with participant urine sample without known contributing factor
  • Presence of a penile implant or stent(s) in the urethra or prostate
  • PSA > 10 ng/ml unless prostate cancer is ruled out by . If PSA is > 4 ng/ml and ≤ 10 ng/ml, prostate cancer must be ruled out to the satisfaction of the investigator via additional tests including digital rectal exam (DRE) and/or biopsy
  • Sensitivity to RT-310
  • Unable to undergo magnetic resonance imaging (MRI) such as presence of cardiac pacemaker or implanted cardiac defibrillator
  • Parkinson's disease or other neurologic disease that may impact bladder function such as stroke, , multiple sclerosis
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    RT-310 Cohort 1

    Combination Product: RT-310 implant Cohort 1

    Combination Product: RT-310

  • Experimental
    RT-310 Cohort 2

    Combination Product: RT-310 Implant Cohort 2

    Combination Product: RT-310

Interventions

  • Combination productRT-310

    Combination Product: RT-310 Implant for Investigational Treatment of Lower Urinary Tract Symptoms Secondary to BPH (Benign Prostatic Hyperplasia)

06

What researchers measure

Primary outcomes

  1. Absence of unanticipated adverse events (UAEs) not listed in the protocol or Adverse Events (AEs) that meet the protocol definition of Serious Adverse Events (SAEs)

    Adverse events

    Time frame: Baseline to Day 180

Secondary outcomes

  1. Change in prostate volume

    Transrectal ultrasound

    Time frame: Baseline to Day 180

  2. Change in IPSS

    International Prostate Symptom Score (IPSS); IPSS scores range from 0 (no symptoms) to 35 (severe symptoms)

    Time frame: Baseline to Day 180

  3. Uroflowmetry measure of Qmax

    Uroflowmetry measure of peak flow rate Qmax (mL/s)

    Time frame: Baseline to Day 180

  4. Uroflowmetry measure of Qave

    Uroflowmetry measure of average flow rate, Qave (mL/s)

    Time frame: Baseline to Day 180

  5. Uroflowmetry measure of voided volume

    Uroflowmetry measure of voided volume (mL)

    Time frame: Baseline to Day 180

  6. PVR

    Post void residual (PVR) measurement

    Time frame: Baseline to Day 180

07

Study locations

4 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in May 2025, 12 months.

Of 26 industry-sponsored phase 1 interventional studies under Prostatic Hyperplasia, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 4. This study's 12 months is above that.

Counting every sponsor, half of 34 studies reached it within 3 months; a quarter within 1 and three quarters within 6.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Dec 2025 → May 2025 and completion Dec 2027 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2023
First posted
Nov 18, 2023
StartActual
Apr 19, 2024
Primary completionActual
May 6, 2025was Dec 2025
CompletionEst.
Nov 2026was Dec 2027
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2025→May 6, 2025 (actual)
Nov 2, 2026
Study completion
Dec 2027→Nov 2026
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Primary completion Dec 2025→May 6, 2025 (now actual)
    Study completion Dec 2027→Nov 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06136819
Lead sponsor
Resurge Therapeutics Inc.
Responsible party
Sponsor
First posted
Nov 18, 2023
Start date
Apr 19, 2024
Primary completion
May 6, 2025
Completion
Nov 2026 (estimated)
Last update
Nov 2, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: RT-310

Start the discussion